OSR Holdings, Inc. (OSRH)

NCM – Real Time Price. Currency in USD

0.37

-0.02 (-4.61%)

Market open: Aug 12, 2026, 11:36 AM EDT

0.40

+0.01 (3.63%)

Previous after-hours: Aug 11, 2026, 7:49 PM EDT

11.08.2026

OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development

Founder and CEO addresses the Company's Nasdaq listing status and accelerating subsidiary business development BELLEVUE, WA / ACCESS Newswire / August 11, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from its Chief Executive Officer to shareholders. Dear Shareholders, Today marks five business days before August 18, the practical deadline by which the Nasdaq is expected to communicate its determination regarding OSRH's continued listing if our stock price has not regained the minimum bid price requirement of $1.00 per share as of the market close.

07.08.2026

OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program

BELLEVUE, WA / ACCESS Newswire / August 7, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today issued a clarification regarding its press release dated July 31, 2026 concerning the Nasdaq Stock Market ("Nasdaq") and the Company's Shareholder Loyalty CVR Program. The Company is clarifying that the statement in the prior release, "The communication affirms that our loyalty program is additive and gives shareholders clarity," should not be interpreted as indicating that Nasdaq has approved or endorsed the Shareholder Loyalty CVR Program.

03.08.2026

Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform

Encouraging data from two glioblastoma studies are expected to be submitted for publication in the coming months BELLEVUE, WA / ACCESS Newswire / August 3, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today announced that its subsidiary Vaximm AG has completed the analysis of results from two clinical studies evaluating VXM01, an oral DNA vaccine targeting the vascular endothelial growth factor receptor 2 (VEGFR-2), in patients with recurrent glioblastoma. Prof. Wolfgang Wick, M.D.

Videos

No Data

There is no data to display

Press releases

11.08.2026

OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development

07.08.2026

OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program

03.08.2026

OSR Holdings, Inc. (OSRH)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

OSR Holdings, Inc. (OSRH)

OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development

OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program

Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform

Videos

No Data

Press releases

OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development

OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program

Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform

OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development

OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program

Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform

Videos

No Data

Press releases

OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development

OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program

Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform

Search stocks

OSR Holdings, Inc. (OSRH)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

OSR Holdings, Inc. (OSRH)

OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development

OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program

Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform

Videos

No Data

Press releases

OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development

OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program

Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform

OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development

OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program

Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform

Videos

No Data

Press releases

OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development

OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program

Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform